| Latest Inovio Biomed News Headlines |
| Date | Time | Source | |
| 03/05/2008 | 6:00AM | PRNUS | Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
LOS ANGELES, March 5 /PRNewswire/ -- Vista Partners announced today that it has updated coverage and has issued a $3.52 price target on Inovio Biomedical Corporation (AMEX:INO). "Inovio has compelling pre-clinical and clinical data regarding the ability of their technology to significantly enhance the potency of DNA... More...>> |
| 06/27/2007 | 6:00AM | PRNUS | Vista Partners Updates Coverage on Inovio Biomedical Corporation (AMEX: INO), Maintains $8.30 Price Target
LOS ANGELES, June 27 /PRNewswire/ -- Vista Partners announced today that it has updated coverage and maintains an $8.30 price target on Inovio Biomedical Corporation (AMEX:INO). "Inovio has compelling pre-clinical and clinical data regarding the ability of their technology to significantly enhance the potency of DNA... More...>> |
| 05/30/2007 | 11:30AM | PRNUS | Inovio Biomedical to Present at American Society of Gene Therapy Meeting
SAN DIEGO, May 30 /PRNewswire-FirstCall/ -- Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA-based DNA vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today that the company will make multiple presentations regarding its... More...>> |
| 03/27/2007 | 6:30AM | PRNUS | Vista Partners Updates Coverage on Inovio Biomedical Corporation
LOS ANGELES, March 27 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Inovio Biomedical Corporation (AMEX:INO). Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. Ross Silver of... More...>> |
| 12/13/2006 | 7:00AM | PRNUS | SLON, IPSU and INO Update the Investment Community in All-New Interviews With WallSt.net
NEW YORK, Dec. 13 /PRNewswire/ -- On December 5, Steve Casciola, President and CEO of Salon City, Inc. (Pink Sheets: SLON) updated the investment community in an all-new interview with http://www.wallst.net/. Interview highlights include detailed discussions on the following topics:
- size of the worldwide beauty... More...>> |
| 12/13/2006 | 7:00AM | PRNUS | SLON, IPSU and INO Update the Investment Community in All-New Interviews With WallSt.net
NEW YORK, Dec. 13 /PRNewswire/ -- On December 5, Steve Casciola, President and CEO of Salon City, Inc. (Pink Sheets: SLON) updated the investment community in an all-new interview with http://www.wallst.net/. Interview highlights include detailed discussions on the following topics:
- size of the worldwide beauty... More...>> |
| 11/03/2006 | 8:30AM | PRNUS | Vista Partners Initiates Coverage on Inovio Biomedical Corporation
SAN FRANCISCO, Nov. 3 /PRNewswire-FirstCall/ -- Vista Partners announced today that it has initiated coverage on Inovio Biomedical Corporation (AMEX:INO). Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. Ross... More...>> |
| 06/05/2006 | 7:35AM | PRNUS | Vical Highlights DNA Vaccine Technology Advances at ASGT Annual Meeting
SAN DIEGO, June 5 /PRNewswire-FirstCall/ -- Vical Incorporated (NASDAQ:VICL) researchers presented data from several of the company's DNA vaccine development programs at the annual meeting of the American Society of Gene Therapy (May 31 - June 4).
"Several lines of preclinical research using Vical's DNA vaccine technology... More...>> |
| 07/18/2005 | 7:00AM | PRNUS | Vical Begins Phase 1 Trial of Gene-Based IL-2 With Inovio Electroporation Technology
Vical Begins Phase 1 Trial of Gene-Based IL-2 With Inovio
Electroporation Technology
SAN DIEGO, July 18 /PRNewswire-FirstCall/ -- Vical Incorporated (NASDAQ:VICL)
and Inovio Biomedical Corporation (AMEX:INO) announced today the initiation of
a human Phase 1 study of an investigational method of delivering interleukin-2
(IL-2... More...>> |